-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion Announces Data From Its Phase 2 Study Of EVX- In Participants With Advanced Melanoma Demonstrates Induced Immune Responses, Underlines Predictive Performance

Benzinga·11/06/2026 16:05:12
Listen to the news

Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 in patients with advanced melanoma (skin cancer).

The data demonstrate potent EVX-01 induced immune responses and further underline the strong predictive performance of Evaxion’s AI-Immunology™ platform. It will be presented in both an oral and a poster session today and tomorrow respectively at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona.